...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: you won’t see anyone buying this

 My initial shares from the spinoff acquired in 2013 were valued by Fidelity at .38 USD.  Yes dilution is bad but since the warrants would only be exercised when the share price was over .85,  I would then feel better about this investment.  The many ZHLCF Shares I acquired later average .27 USD. Obviously underwater on these but I have regarded this as a privately held company of which the OTC trade price is not all that relevant.

Share
New Message
Please login to post a reply